Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Non-Current Deffered Revenue (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $8.7 million as the latest value for Q3 2025.

  • Quarterly Non-Current Deffered Revenue fell 24.3% to $8.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Sep 2025, down 24.3% year-over-year, with the annual reading at $11.0 million for FY2024, 26.36% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $8.7 million at Orchestra BioMed Holdings, down from $9.6 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $14.9 million in Q4 2023, with the low at $5.6 million in Q3 2022.
  • Average Non-Current Deffered Revenue over 4 years is $11.7 million, with a median of $12.7 million recorded in 2024.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 147.23% in 2023, then decreased 26.36% in 2024.
  • Over 4 years, Non-Current Deffered Revenue stood at $13.1 million in 2022, then grew by 13.89% to $14.9 million in 2023, then dropped by 26.36% to $11.0 million in 2024, then fell by 21.2% to $8.7 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $8.7 million, $9.6 million, and $10.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.